Applied Therapeutics Stock Forecast, Price & News

Applied Therapeutics (NASDAQ:APLT) Frequently Asked Questions

Is Applied Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last year. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Applied Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in APLT, but not buy additional shares or sell existing shares.
View analyst ratings for Applied Therapeutics or view top-rated stocks.

How has Applied Therapeutics' stock been impacted by COVID-19?

Applied Therapeutics' stock was trading at $29.59 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, APLT stock has decreased by 63.6% and is now trading at $10.77.
View which stocks have been most impacted by COVID-19.

When is Applied Therapeutics' next earnings date?

Applied Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for Applied Therapeutics.

How were Applied Therapeutics' earnings last quarter?

Applied Therapeutics, Inc. (NASDAQ:APLT) issued its earnings results on Friday, November, 12th. The company reported ($1.09) EPS for the quarter, beating the Zacks' consensus estimate of ($1.15) by $0.06.
View Applied Therapeutics' earnings history.

What price target have analysts set for APLT?

2 brokers have issued 12-month price targets for Applied Therapeutics' stock. Their forecasts range from $10.00 to $35.00. On average, they anticipate Applied Therapeutics' share price to reach $22.50 in the next twelve months. This suggests a possible upside of 108.9% from the stock's current price.
View analysts' price targets for Applied Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Applied Therapeutics' key executives?

Applied Therapeutics' management team includes the following people:

• Shoshana Shendelman, Chairman, President, CEO & Secretary (LinkedIn Profile)
• Charles Silberstein, CFO & Head-Business Development (LinkedIn Profile)
• Riccardo Perfetti, Chief Medical Officer (LinkedIn Profile)
• Adam Hansard, Chief Commercial Officer
• Chids Mahadevan, Chief Accounting Officer & Vice President-Finance

Who are some of Applied Therapeutics' key competitors?

Some companies that are related to Applied Therapeutics include Day One Biopharmaceuticals (DAWN), MannKind (MNKD), Design Therapeutics (DSGN), PMV Pharmaceuticals (PMVP), Vectura Group (VEGPF), DICE Therapeutics (DICE), MacroGenics (MGNX), Edgewise Therapeutics (EWTX), Merus (MRUS), Arcturus Therapeutics (ARCT), CannTrust (CNTTF), Amphastar Pharmaceuticals (AMPH), Seres Therapeutics (MCRB), Repare Therapeutics (RPTX) and Tango Therapeutics (TNGX).
View all of APLT's competitors.

What other stocks do shareholders of Applied Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include Enterprise Products Partners (EPD), Pfizer (PFE), Advanced Micro Devices (AMD), Energy Transfer (ET), Micron Technology (MU), NVIDIA (NVDA), Verizon Communications (VZ), AbbVie (ABBV), Walt Disney (DIS) and Raytheon Technologies (RTX).

When did Applied Therapeutics IPO?

(APLT) raised $60 million in an initial public offering on the week of May 13th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank served as the underwriters for the IPO and Baird was co-manager.

What is Applied Therapeutics' stock symbol?

Applied Therapeutics trades on the NASDAQ under the ticker symbol "APLT."

Who are Applied Therapeutics' major shareholders?

Applied Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.94%), Point72 Asset Management L.P. (3.88%), Franklin Resources Inc. (3.19%), Emerald Mutual Fund Advisers Trust (2.37%), Emerald Advisers LLC (2.16%) and Geode Capital Management LLC (1.21%). Company insiders that own Applied Therapeutics stock include Charles Silberstein, Joel S Marcus, Leslie D Funtleyder, Real Estate Equitie Alexandria, Riccardo Perfetti, Shoshana Shendelman and Stacy J Kanter.
View institutional ownership trends for Applied Therapeutics.

Which institutional investors are selling Applied Therapeutics stock?

APLT stock was sold by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, BlackRock Inc., Voya Investment Management LLC, New York State Common Retirement Fund, Emerald Advisers LLC, UBS Group AG, and California State Teachers Retirement System. Company insiders that have sold Applied Therapeutics company stock in the last year include Charles Silberstein, and Riccardo Perfetti.
View insider buying and selling activity for Applied Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Applied Therapeutics stock?

APLT stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Dimensional Fund Advisors LP, Geode Capital Management LLC, Two Sigma Investments LP, Barclays PLC, Deutsche Bank AG, Millennium Management LLC, and Squarepoint Ops LLC. Company insiders that have bought Applied Therapeutics stock in the last two years include Real Estate Equitie Alexandria, Shoshana Shendelman, and Stacy J Kanter.
View insider buying and selling activity for Applied Therapeutics or or view top insider-buying stocks.

How do I buy shares of Applied Therapeutics?

Shares of APLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Applied Therapeutics' stock price today?

One share of APLT stock can currently be purchased for approximately $10.77.

How much money does Applied Therapeutics make?

Applied Therapeutics has a market capitalization of $282.35 million. The company earns $-93.96 million in net income (profit) each year or ($4.14) on an earnings per share basis.

How many employees does Applied Therapeutics have?

Applied Therapeutics employs 24 workers across the globe.

What is Applied Therapeutics' official website?

The official website for Applied Therapeutics is www.appliedtherapeutics.com.

Where are Applied Therapeutics' headquarters?

Applied Therapeutics is headquartered at 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173.

How can I contact Applied Therapeutics?

Applied Therapeutics' mailing address is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. The company can be reached via phone at (212) 220-9226 or via email at [email protected].